Sign in

CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Bicara Therapeutics Inc.

Sign in to watch
Ticker
BCAX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
617-468-4219
Business address
116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
  1. 4 Planned sale Chief Medical Officer sold 22,000 shares at $18.45 ($405,900)
  2. 4 Planned sale Chief Financial Officer sold 6,415 shares at $18.23 ($116,931)
  3. 4 Planned sale Chief Financial Officer sold 30,385 shares at an average $18.21 ($553,198)
  4. 4 Planned sale President and COO sold 50,500 shares at an average $18.06 ($911,842)
  5. 4 Planned sale Chief Legal Officer sold 33,807 shares at $14.75 ($498,653)
  6. 4 Planned sale Chief Legal Officer sold 15,829 shares at $11.49 ($181,875)
  7. 4 Planned sale Chief Legal Officer sold 15,829 shares at $10.43 ($165,096)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Planned sale Chief Legal Officer sold 79,146 shares at an average $12.90 ($1,021,211)
  17. 4 Open-market buy Director bought 1,833,000 shares at $18.00 ($32,994,000)
  18. 4 Conversion Former 10% Owner acquired 1,960,425 shares (conversion)
  19. 4 Conversion See Remark 1 acquired 1,013,853 shares (conversion)
  20. 4 Conversion See Remark 1 acquired 1,115,333 shares (conversion)

Page 4 of 6 · 107 filings